Get the Stockscreener App
9.44
1.67%
-0.16
After Hours:
9.29
-0.15
-1.59%
Quoin Pharmaceuticals Ltd Adr stock is traded at $9.44, with a volume of 38,713.
It is down -1.67% in the last 24 hours and down -32.52% over the past month.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
See More
Previous Close:
$9.60
Open:
$9.69
24h Volume:
38,713
Relative Volume:
0.11
Market Cap:
$15.26M
Revenue:
-
Net Income/Loss:
$-12.25M
P/E Ratio:
-0.0204
EPS:
-463.5156
Net Cash Flow:
$-10.77M
1W Performance:
-9.67%
1M Performance:
-32.52%
6M Performance:
+15.54%
1Y Performance:
-20.90%
1-Day Range:
$9.11
$9.84
1-Week Range:
$9.11
$10.60
52-Week Range:
$5.01
$41.80
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Company Profile
Name
Quoin Pharmaceuticals Ltd Adr
Sector
Industry
Phone
97299741444
Address
23 HATA'AS STREET, KFAR SABA
Compare QNRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNRX
Quoin Pharmaceuticals Ltd Adr
|
9.44 | 15.52M | 0 | -12.25M | -10.77M | -463.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Latest News
Quoin seeks orphan drug status in Japan for Netherton Syndrome therapy By Investing.com - Investing.com India
Quoin seeks orphan drug status in Japan for Netherton Syndrome therapy - Investing.com
ETFs Investing in Quoin Pharmaceuticals. Ltd Sponsored ADR Stocks - TradingView — Track All Markets
Quoin Pharmaceuticals Ltd – ADR trading resumes - MSN
Quoin Pharmaceuticals (NASDAQ:QNRX) Shares Up 24.5% – Still a Buy? - Defense World
Pre Market Movers: PRAX, SPRC, QNRX Set The Pace - RTTNews
Wall Street analysts’ outlook for Quoin Pharmaceuticals Ltd ADR (QNRX) - setenews.com
US Stocks Mixed; Sea Shares Gain After Q3 ResultsMSP Recovery (NASDAQ:MSPR), Outset Medical (NASDAQ:OM) - Benzinga
Quoin Pharmaceuticals stock soars after achieving target rapamycin loadings - Investing.com
Quoin Pharmaceuticals stock soars after achieving target rapamycin loadings By Investing.com - Investing.com Philippines
US Stock Market today: Nasdaq, S&P 500 open lower amid elevated tech valuation concerns, Dow Jones up 0.17% - Mint
Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results - Sahm
Zoetis (NYSE:ZTS) & Quoin Pharmaceuticals (NASDAQ:QNRX) Head to Head Survey - Defense World
Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025 - The Manila Times
Quoin Pharmaceuticals stock rises after positive pediatric trial data - Investing.com
Quoin Pharmaceuticals Ltd – ADR trading halted, volatility trading pause - MSN
Quoin Pharmaceuticals stock rises after positive pediatric trial data By Investing.com - Investing.com UK
Quoin Pharmaceuticals announces FDA granted ODD to QRX003 - TipRanks
Quoin Pharmaceuticals director Langer buys $128,640 in ADSs - Investing.com
Quoin Pharmaceuticals, Ltd.American Depositary Shares (Nasdaq:QNRX) Stock Quote | Pittsburgh Post-Gazette - FinancialContent
Quoin Pharmaceuticals (NASDAQ:QNRX) Receives Sell (E) Rating from Weiss Ratings - Defense World
Pre Market Movers: NBTX, IMTX, QNRX See Big Swings - RTTNews
Why NioCorp Developments Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - inkl
Quoin Pharma (QNRX) Stock Skyrockets 150% on Funding Deal – What’s Next? - ts2.tech
Quoin Pharmaceuticals (QNRX) Stock Is Skyrocketing Friday: What's Going On? - Benzinga
Quoin Pharmaceuticals stock soars after securing premium-priced funding - Investing.com
Quoin Pharmaceuticals secures up to $104.5 million in private placement - Investing.com
Quoin Pharmaceuticals. Ltd Sponsored ADR Financial Disclosures & SEC Filings - TradingView
Quoin Pharmaceuticals finalizes separation agreement with former CFO - Investing.com
Quoin Pharmaceuticals (NASDAQ:QNRX) Shares Up 2.8% – Still a Buy? - Defense World
Analysts Offer Insights on Healthcare Companies: Myomo (MYO), Quoin Pharmaceuticals (QNRX) and RegenXBio (RGNX) - The Globe and Mail
Quoin (QNRX) Q2 Loss Beats Estimates - The Motley Fool
Quoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 2025 - The Globe and Mail
Quoin Pharmaceuticals stock rises after positive clinical updates - Investing.com India
Quoin Pharmaceuticals advances rare disease pipeline with two active trials - Investing.com India
Quoin Pharmaceuticals (NASDAQ:QNRX) Stock Price Down 2.9% – Here’s Why - Defense World
Quoin Pharmaceuticals (QNRX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Quoin Pharmaceuticals CFO Gordon Dunn to depart following mutual agreement - Investing.com
Quoin Pharmaceuticals receives FDA rare pediatric disease designation for QRX003 - Investing.com
Why Quoin Pharmaceuticals (QNRX) Stock Is Exploding Higher Wednesday - Benzinga
Quoin Pharmaceuticals regains Nasdaq compliance with bid price - Investing.com
Quoin Pharmaceuticals Ltd Share Price ADR EACH REPR 35 ORD SPON - Hargreaves Lansdown
QNRX Stock Plummets to 52-Week Low of $0.17 Amid Market Struggles - Investing.com
Quoin Pharmaceuticals announces ADS ratio change to meet Nasdaq requirements - Investing.com
Quoin Pharmaceuticals reports positive clinical data for rare disease treatment - Investing.com
QNRX Stock Plummets to 52-Week Low at $0.26 Amid Market Struggles - Investing.com
Quoin reports positive results in Netherton Syndrome study - Investing.com
Quoin Pharmaceuticals CEO Michael Myers acquires $250,000 in shares - Investing.com
Quoin Pharmaceuticals granted extension to meet Nasdaq listing - Investing.com
Quoin Pharmaceuticals COO acquires $28,737 in company shares - Investing.com India
Quoin Pharmaceuticals (QNRX) Stock Trends and Sentiment 2025 - MarketBeat
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):